burosumab-twza (crysvita) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Fast Track FDA

Active Ingredient History

  • Now
Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication approved 2018 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2556.3900 - $10183.8700
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

burosumab | burosumab-twza | krn23 | krn-23


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue